Defying "the norm" and creating a path to a better future for patients.
Founder & CEO
Dan has experience managing therapeutic antibody projects from preclinical stage through clinical trials. He witnessed first-hand issues the surrounding conventional antivenom and decided to act.
Deepankar Roy, PhD
Co-Founder & COO
Deepankar has expertise in drug manufacturing, project management, and business development. Familiar with and connected to Indian market.
Alex Capovilla, PhD
Co-Founder & CSO
Alex has an extensive background in recombinant antibody engineering complemented by a history of bringing drugs to market overseas.